Rule/Regulation Violated:
R9-10-120.F.4.a-c. Opioid Prescribing and Treatment <br> F. For a health care institution where opioids are administered as part of treatment or where a patient is provided assistance in the self-administration of medication for a prescribed opioid, including a health care institution in which an opioid may be prescribed or ordered as part of treatment, a medical director, a manager as defined in R9-10-801, or a provider, as applicable to the health care institution, shall: <br> 4. Except as provided in subsection (H), ensure that an individual authorized by policies and procedures to administer an opioid in treating a patient or to provide assistance in the self-administration of medication for a prescribed opioid: <br> a. Before administering an opioid or providing assistance in the self-administration of medication for a prescribed opioid in compliance with an order as part of the treatment for a patient, identifies the patient's need for the opioid; <br> b. Monitors the patient's response to the opioid; and <br> c. Documents in the patient's medical record: <br> i. An identification of the patient ' s need for the opioid before the opioid was administered or assistance in the self-administration of medication for a prescribed opioid was provided, and <br> ii. The effect of the opioid administered or for which assistance in the self-administration of medication for a prescribed opioid was provided.
Evidence/Findings:
<p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">Based on documentation review, record review, and interview, the manager failed to ensure an individual authorized to administer opioids identified the resident's need for an opioid before administering the opioid and monitored the resident's response to the opioid for residents who did not have an active malignancy or an end-of-life condition. </span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">Findings include: </span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">1. Review of the facility's policies and procedures revealed a policy titled, “Medication & Treatment,” which stated, “11. Administration of opioid medications requires assessment of resident pain with the use of the 0-10 verbal pain scale or faces scale as applicable. a. The assessment of pain is conducted prior to administration. b. Within an hour after administration the resident should be assessed for response and effectiveness of the opioid administration. c. documentation of the resident’s pain before administration of the opioid and the effect of the opioid administration should be documented on the MAR or eMAR.”</span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">2. Review of R4’s medical record revealed a current service plan indicating R4 was at the directed level of care and received medication administration. The service did not indicate R4 was on hospice, was receiving treatment for an active malignancy, or had an end-of-life condition.</span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">3. Review of R4’s medical record revealed a medication administration record (MAR), which revealed R4 received Tramadol HCI oral tablet 50 MG three times a day for the entire month of July 2025.</span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">4. Review of R4’s medical record revealed a medication order for Tramadol HCI 50 MG, the start date was listed as November 2024. </span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">5. Review of R4’s medical record did not reveal documentation of R4’s pain level or the effectiveness of the Tramadol HCI 50 MG.</span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">6. In an interview, E5 reported E5 did not know scheduled opioid documentation was to also include the resident’s pain scale and the effectiveness of the opioid medication. </span></p><p><br></p><p><br></p><p><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">7. </span><span style="color: rgb(0, 0, 0); font-family: Arial, sans-serif; font-size: 11pt; background-color: transparent;">I</span><span style="color: rgb(34, 34, 34); font-family: Arial, sans-serif; font-size: 11pt;">n an exit interview, the findings were reviewed with E1 and no additional information was provided.</span></p>
Permanent Solution:
On 8/13 Health and Wellness Director conducted mandatory re-training for all nursing staff and medication technician’s on the Medication and Treatment Administration/Assistance policy, including:
Correct timing and documentation of pain scales for scheduled opioids for residents not on hospice or receiving end of life care, before and after administration.
Health and Wellness Director or designee will review all MAR’s weekly for 4 weeks, then monthly thereafter, for appropriate documentation of pain scale for before and after administration on scheduled opioid dose for residents not on hospice or receiving end of life care.
Summary:
No deficiencies were found during the on-site investigation of complaint 00149306 conducted on October 30, 2025.